1 recruiting, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Theodore Laetsch: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors PEEL-224, Vincristine, Temozolomide (TMZ) - Refractory Solid Tumors, Relapsed Solid Tumors | Phase 1 / Phase 2 | Recruiting | Theodore Laetsch | 59 | 2025-03-23 | 2026-10-06 |
| A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors Erlotinib, Sirolimus - Relapsed / Recurrent Germ Cell Tumors | Phase 2 | Terminated | Theodore Laetsch | 4 | 2014-01-08 | 2019-02-26 |
Neoplasms, Germ Cell and Embryonal (1) · Neuroblastoma (1) · Recurrence (1) · Rhabdomyosarcoma (1)
Erlotinib Hydrochloride (1) · Sirolimus (1) · Temozolomide (1) · Vincristine (1)
United States (2)